RECURRENT GRADE 3B FOLLICULAR LYMPHOMA

This study tests a two-step treatment for adults with large B-cell lymphoma that has returned or not responded to standard therapy. First, patients receive tafasitamab and lenalidomide, then a chemotherapy combo called ICE. The goal is to shrink or eliminate cancer before a stem …

This study tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can safely and effectively treat adults with diffuse large B-cell lymphoma that has come back or stopped responding to prior therapy. The drugs work by attaching to cancer cells and e…

This study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 adults will receive the combination to evaluate safety, the bes…

This study is for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It tests a combination of two drugs: epcoritamab, which helps the immune system attack cancer cells, and ibrutinib, which blocks signals that help cance…

This phase 1 trial is testing a CAR-T cell therapy (axicabtagene ciloleucel) in 20 adults with HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer c…

This study tests a drug called odronextamab given before CAR-T cell therapy in people with large B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this bridging therapy can control the cancer long enough for patients to successfully unde…

This study tests whether giving two drugs—golcadomide and rituximab—before CAR-T cell therapy can help more people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to control the disease so patients can proceed to CAR-T, whi…